CN101407511A - 一种结晶型的咪唑-5-羧酸衍生物 - Google Patents
一种结晶型的咪唑-5-羧酸衍生物 Download PDFInfo
- Publication number
- CN101407511A CN101407511A CNA2007100941310A CN200710094131A CN101407511A CN 101407511 A CN101407511 A CN 101407511A CN A2007100941310 A CNA2007100941310 A CN A2007100941310A CN 200710094131 A CN200710094131 A CN 200710094131A CN 101407511 A CN101407511 A CN 101407511A
- Authority
- CN
- China
- Prior art keywords
- formula
- polar solvent
- compound
- acid
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
波长(cm-1) | 透光率(%) | 波长(cm-1) | 透光率(%) |
763 | 52 | 837 | 40 |
906 | 45 | 941 | 57 |
987 | 41 | 1020 | 67 |
1074 | 55 | 1136 | 52 |
1159 | 51 | 1256 | 71 |
1383 | 45 | 1410 | 43 |
1458 | 52 | 1483 | 47 |
1518 | 48 | 1732 | 71 |
1759 | 77 | 2871 | 41 |
2907 | 40 | 2934 | 42 |
2955 | 44 | 2987 | 43 |
Claims (15)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100941310A CN101407511B (zh) | 2007-10-11 | 2007-10-11 | 一种结晶型的咪唑-5-羧酸衍生物 |
US12/682,561 US8178569B2 (en) | 2007-10-11 | 2008-10-10 | Crystalline imidazole-5-carboxylic acid derivative |
JP2010528263A JP5303765B2 (ja) | 2007-10-11 | 2008-10-10 | 結晶性イミダゾール−5−カルボン酸誘導体 |
PCT/CN2008/001715 WO2009049495A1 (fr) | 2007-10-11 | 2008-10-10 | Dérivé acide imidazol-5-carboxylique cristallin |
PL08838798T PL2213669T3 (pl) | 2007-10-11 | 2008-10-10 | Krystaliczna pochodna kwasu imidazolo-5-karboksylowego |
EP08838798.0A EP2213669B1 (en) | 2007-10-11 | 2008-10-10 | Crystalline imidazol-5-carboxylic acid derivate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100941310A CN101407511B (zh) | 2007-10-11 | 2007-10-11 | 一种结晶型的咪唑-5-羧酸衍生物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101407511A true CN101407511A (zh) | 2009-04-15 |
CN101407511B CN101407511B (zh) | 2013-01-09 |
Family
ID=40566990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100941310A Active CN101407511B (zh) | 2007-10-11 | 2007-10-11 | 一种结晶型的咪唑-5-羧酸衍生物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8178569B2 (zh) |
EP (1) | EP2213669B1 (zh) |
JP (1) | JP5303765B2 (zh) |
CN (1) | CN101407511B (zh) |
PL (1) | PL2213669T3 (zh) |
WO (1) | WO2009049495A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103012377A (zh) * | 2011-09-27 | 2013-04-03 | 江苏艾力斯生物医药有限公司 | 一种咪唑-5-羧酸酯的重结晶方法 |
CN103965171A (zh) * | 2014-04-30 | 2014-08-06 | 上海艾力斯医药科技有限公司 | 一种阿利沙坦酯的制备方法 |
CN104610232A (zh) * | 2013-11-01 | 2015-05-13 | 深圳信立泰药业股份有限公司 | 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物 |
CN106188012A (zh) * | 2014-06-20 | 2016-12-07 | 深圳信立泰药业股份有限公司 | 一种阿利沙坦酯结晶及其制备方法及含有该结晶的药物组合物 |
CN114163391A (zh) * | 2021-12-14 | 2022-03-11 | 迪嘉药业集团有限公司 | 一种坎地沙坦中间体及坎地沙坦的制备方法 |
CN115947722A (zh) * | 2017-10-24 | 2023-04-11 | 深圳信立泰药业股份有限公司 | 阿利沙坦酯钠盐晶型及含有所述钠盐晶型的药物组合物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101024643A (zh) | 2006-02-20 | 2007-08-29 | 上海艾力斯医药科技有限公司 | 咪唑-5-羧酸类衍生物、制备方法及其应用 |
CN101317842A (zh) * | 2007-06-07 | 2008-12-10 | 上海艾力斯医药科技有限公司 | 一种咪唑-5-羧酸衍生物的治疗用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT398202B (de) * | 1991-10-04 | 1994-10-25 | Chem Pharm Forsch Gmbh | Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung |
CA2534451A1 (en) * | 2003-07-31 | 2005-02-10 | Nicox S.A. | Angiotensin ii receptor blocker derivatives |
CN101024643A (zh) * | 2006-02-20 | 2007-08-29 | 上海艾力斯医药科技有限公司 | 咪唑-5-羧酸类衍生物、制备方法及其应用 |
AU2006351517B8 (en) | 2006-12-06 | 2012-01-19 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | The salts of imidazol-5-carboxylic acid derivatives, preparation methods and use thereof |
-
2007
- 2007-10-11 CN CN2007100941310A patent/CN101407511B/zh active Active
-
2008
- 2008-10-10 WO PCT/CN2008/001715 patent/WO2009049495A1/zh active Application Filing
- 2008-10-10 EP EP08838798.0A patent/EP2213669B1/en not_active Not-in-force
- 2008-10-10 PL PL08838798T patent/PL2213669T3/pl unknown
- 2008-10-10 US US12/682,561 patent/US8178569B2/en not_active Expired - Fee Related
- 2008-10-10 JP JP2010528263A patent/JP5303765B2/ja not_active Expired - Fee Related
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103012377A (zh) * | 2011-09-27 | 2013-04-03 | 江苏艾力斯生物医药有限公司 | 一种咪唑-5-羧酸酯的重结晶方法 |
CN109320501B (zh) * | 2013-11-01 | 2021-06-01 | 深圳信立泰药业股份有限公司 | 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物 |
CN104610232A (zh) * | 2013-11-01 | 2015-05-13 | 深圳信立泰药业股份有限公司 | 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物 |
CN111018841B (zh) * | 2013-11-01 | 2023-04-07 | 深圳信立泰药业股份有限公司 | 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物 |
CN109320501A (zh) * | 2013-11-01 | 2019-02-12 | 深圳信立泰药业股份有限公司 | 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物 |
CN104610232B (zh) * | 2013-11-01 | 2019-09-20 | 深圳信立泰药业股份有限公司 | 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物 |
CN111018841A (zh) * | 2013-11-01 | 2020-04-17 | 深圳信立泰药业股份有限公司 | 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物 |
CN103965171A (zh) * | 2014-04-30 | 2014-08-06 | 上海艾力斯医药科技有限公司 | 一种阿利沙坦酯的制备方法 |
CN106188012A (zh) * | 2014-06-20 | 2016-12-07 | 深圳信立泰药业股份有限公司 | 一种阿利沙坦酯结晶及其制备方法及含有该结晶的药物组合物 |
CN106188012B (zh) * | 2014-06-20 | 2018-11-30 | 深圳信立泰药业股份有限公司 | 一种阿利沙坦酯结晶及其制备方法及含有该结晶的药物组合物 |
CN115947722A (zh) * | 2017-10-24 | 2023-04-11 | 深圳信立泰药业股份有限公司 | 阿利沙坦酯钠盐晶型及含有所述钠盐晶型的药物组合物 |
CN115947722B (zh) * | 2017-10-24 | 2024-04-02 | 深圳信立泰药业股份有限公司 | 阿利沙坦酯钠盐晶型及含有所述钠盐晶型的药物组合物 |
CN114163391A (zh) * | 2021-12-14 | 2022-03-11 | 迪嘉药业集团有限公司 | 一种坎地沙坦中间体及坎地沙坦的制备方法 |
CN114163391B (zh) * | 2021-12-14 | 2024-02-02 | 迪嘉药业集团股份有限公司 | 一种坎地沙坦中间体及坎地沙坦的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US8178569B2 (en) | 2012-05-15 |
EP2213669A4 (en) | 2011-02-16 |
JP5303765B2 (ja) | 2013-10-02 |
PL2213669T3 (pl) | 2015-12-31 |
EP2213669A9 (en) | 2011-05-04 |
CN101407511B (zh) | 2013-01-09 |
EP2213669B1 (en) | 2015-07-29 |
WO2009049495A1 (fr) | 2009-04-23 |
JP2011500515A (ja) | 2011-01-06 |
EP2213669A1 (en) | 2010-08-04 |
US20100292286A1 (en) | 2010-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101407511B (zh) | 一种结晶型的咪唑-5-羧酸衍生物 | |
CA2706536C (en) | Amorphous form of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same | |
CN100546985C (zh) | 非布他特微晶及其组合物 | |
JP7051638B2 (ja) | エスシタロプラム医薬組成物 | |
CN102405219A (zh) | 用于治疗copd的5-吡唑基-2-吡啶酮衍生物的对甲苯磺酸盐 | |
KR20010074472A (ko) | 신규의 결정질 형태의 항바이러스성 벤즈이미다졸 화합물 | |
KR20140066705A (ko) | 약제 제제에 사용하기 위해 특정한 입자 크기 분포 범위와 비표면적 범위를 갖는 n-[5-(아미노설포닐)-4-메틸-1,3-티아졸-2-일]-n-메틸-2-[4-(2-피리디닐)페닐]아세트아미드 메실레이트 일수화물 | |
CN101597272B (zh) | 艾拉莫德的钾盐化合物,其制备方法和药物应用 | |
CA2773003A1 (en) | Orally disintegrating pharmaceutical dosage form containing aripiprazole | |
AU2018296476B2 (en) | Pharmaceutical composition and method for preparing same | |
CN101993417B (zh) | 磷酸二甲啡烷的稳定晶型 | |
KR101121589B1 (ko) | 안정성이 향상된 무정형 아데포비어 디피복실 고체분산체 및 이의 제조방법 | |
CN103690499B (zh) | 一种稳定的晶i型阿戈美拉汀片剂及其制备方法 | |
CN103655499B (zh) | 一种稳定的晶x型阿戈美拉汀片剂及其制备方法 | |
CN105481758A (zh) | 一种洛美他派晶型ⅰ及其制备方法和用途 | |
CN104418802B (zh) | 瑞巴派特一水合物晶型及其制备方法 | |
CN101333189A (zh) | 适合药用的阿立哌唑晶型、制备方法及药物组合物 | |
CN102666528A (zh) | 晶体cdc7 抑制剂盐 | |
KR101872726B1 (ko) | 텔미사르탄 메탄술폰산염 및 이를 포함하는 약제학적 조성물 | |
KR100837843B1 (ko) | 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물 | |
CN106316964A (zh) | 苯基氨基嘧啶化合物或其盐的多晶型物 | |
CN102093387A (zh) | 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物 | |
CN105348260A (zh) | 达比加群酯氢溴酸盐及其制备方法和应用 | |
CN104257617A (zh) | 盐酸伊托必利口服制剂 | |
CN104666266B (zh) | 一种含有孟鲁司特钠的固体口服制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI ALLIS BIO-PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHANGHAI ALLIS MEDICAL TECHNOLOGY CO., LTD. Effective date: 20090918 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090918 Address after: Zhou Zhu Road, Shanghai, Pudong New Area No. 337 Applicant after: Shanghai Allist Pharmaceuticals, Inc. Address before: Floor 1118, 5 Harley Road, Zhangjiang hi tech park, Shanghai, Pudong New Area Applicant before: SHANGHAI ALLIST PHARMACEUTICALS, Inc. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. Free format text: FORMER OWNER: SHANGHAI ALLIST BIOMEDICAL CO., LTD. Effective date: 20121221 Owner name: SHENZHEN SALUBRIS ASSETS MANAGEMENT CO., LTD. Free format text: FORMER OWNER: SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. Effective date: 20121221 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201318 PUDONG NEW AREA, SHANGHAI TO: 201203 PUDONG NEW ZONE, SHANGHAI CITY Free format text: CORRECT: ADDRESS; FROM: 201203 PUDONG NEW ZONE, SHANGHAI CITY TO: 518040 SHENZHEN, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121221 Address after: 518040 Shenzhen City, Futian District Shennan Road south of Anhui building 1921 Patentee after: Shenzhen Xinlitai Asset Management Co.,Ltd. Address before: 201203 Shanghai City Harley Road, Zhangjiang hi tech Park No. 1118 5 floor Patentee before: SHANGHAI ALLIST PHARMACEUTICALS, Inc. Effective date of registration: 20121221 Address after: 201203 Shanghai City Harley Road, Zhangjiang hi tech Park No. 1118 5 floor Patentee after: SHANGHAI ALLIST PHARMACEUTICALS, Inc. Address before: 201318 Shanghai city Pudong New Area Zhu Zhou Road No. 337 Patentee before: Shanghai Allist Pharmaceuticals, Inc. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20090415 Assignee: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd. Assignor: Shenzhen Xinlitai Asset Management Co.,Ltd. Contract record no.: 2012440020458 Denomination of invention: Crystal type glyoxaline-5-carboxyl acid derivative License type: Common License Record date: 20121227 Application publication date: 20090415 Assignee: SHANGHAI ALLIST PHARMACEUTICAL., Inc. Assignor: Shenzhen Xinlitai Asset Management Co.,Ltd. Contract record no.: 2012440020457 Denomination of invention: Crystal type glyoxaline-5-carboxyl acid derivative License type: Common License Record date: 20121227 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: SHANGHAI ALLIST PHARMACEUTICAL., Inc. Assignor: Shenzhen Xinlitai Asset Management Co.,Ltd. Contract record no.: 2012440020457 Date of cancellation: 20150127 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
ASS | Succession or assignment of patent right |
Owner name: HUIZHOU XINLITAI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHENZHEN SALUBRIS ASSETS MANAGEMENT CO., LTD. Effective date: 20150717 Owner name: SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Effective date: 20150717 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150717 Address after: 516083, No. 42, West Petrochemical Avenue, Dayawan West, Huizhou, Guangdong, Huizhou Patentee after: HUIZHOU XINLITAI PHARMACEUTICAL Co.,Ltd. Patentee after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd. Address before: 518040 Shenzhen City, Futian District Shennan Road south of Anhui building 1921 Patentee before: Shenzhen Xinlitai Asset Management Co.,Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: Lu Wan Document name: Notification of Conformity |
|
DD01 | Delivery of document by public notice |